These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 11751777)

  • 21. In-vitro activity and killing effect of quinupristin/dalfopristin (RP59500) on nosocomial Staphylococcus aureus and interactions with rifampicin and ciprofloxacin against methicillin-resistant isolates.
    Sambatakou H; Giamarellos-Bourboulis EJ; Grecka P; Chryssouli Z; Giamarellou H
    J Antimicrob Chemother; 1998 Mar; 41(3):349-55. PubMed ID: 9578161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group.
    Fagon J; Patrick H; Haas DW; Torres A; Gibert C; Cheadle WG; Falcone RE; Anholm JD; Paganin F; Fabian TC; Lilienthal F
    Am J Respir Crit Care Med; 2000 Mar; 161(3 Pt 1):753-62. PubMed ID: 10712318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
    Tenover FC; Baker CN
    J Antimicrob Chemother; 1997 May; 39 Suppl A():81-5. PubMed ID: 9511069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of vancomycin-resistant enterococci, with a focus on quinupristin-dalfopristin.
    Fuller RE; Drew RH; Perfect JR
    Pharmacotherapy; 1996; 16(4):584-92. PubMed ID: 8840364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in-vitro activity of quinupristin/dalfopristin against Enterococcus spp.
    Williams JD; Maskell JP; Whiley AC; Sefton AM
    J Antimicrob Chemother; 1997 May; 39 Suppl A():41-6. PubMed ID: 9511061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-frequency recovery of quinupristin-dalfopristin-resistant Enterococcus faecium isolates from the poultry production environment.
    Hayes JR; McIntosh AC; Qaiyumi S; Johnson JA; English LL; Carr LE; Wagner DD; Joseph SW
    J Clin Microbiol; 2001 Jun; 39(6):2298-9. PubMed ID: 11376075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
    Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
    J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of quinupristin/dalfopristin alone or in combination with vancomycin on the structure of Enterococcus faecium.
    Lorian V; Fernandes F
    Drugs Exp Clin Res; 1998; 24(2):73-6. PubMed ID: 9675547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections.
    Manzella JP
    Am Fam Physician; 2001 Dec; 64(11):1863-6. PubMed ID: 11764864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to quinupristin-dalfopristin due to mutation of L22 ribosomal protein in Staphylococcus aureus.
    Malbruny B; Canu A; Bozdogan B; Fantin B; Zarrouk V; Dutka-Malen S; Feger C; Leclercq R
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2200-7. PubMed ID: 12069975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium.
    Lorian V; Fernandes F
    J Antimicrob Chemother; 1997 May; 39 Suppl A():63-6. PubMed ID: 9511065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination.
    Griswold MW; Lomaestro BM; Briceland LL
    Am J Health Syst Pharm; 1996 Sep; 53(17):2045-53. PubMed ID: 8870891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of vancomycin-resistant Enterococcus faecium infections with an investigational streptogramin antibiotic (quinupristin/dalfopristin): a report of fifteen cases.
    Dever LL; Smith SM; Dejesus D; Masurekar M; Patel D; Kaminski ZC; Johanson WG
    Microb Drug Resist; 1996; 2(4):407-13. PubMed ID: 9158811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinupristin-dalfopristin versus linezolid for the treatment of vancomycin-resistant Enterococcus faecium bacteraemia: efficacy and development of resistance.
    Chong YP; Lee SO; Song EH; Lee EJ; Jang EY; Kim SH; Choi SH; Kim MN; Jeong JY; Woo JH; Kim YS
    Scand J Infect Dis; 2010 Jul; 42(6-7):491-9. PubMed ID: 20524781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
    Schouten MA; Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quinupristin/dalfopristin: a treatment option for vancomycin-resistant Enterococci.
    Kim MK; Nicolau DP; Nightingale CH; Quintiliani R
    Conn Med; 2000 Apr; 64(4):209-12. PubMed ID: 10812767
    [No Abstract]   [Full Text] [Related]  

  • 37. Susceptibility to RPR 106,972, quinupristin/dalfopristin and erythromycin among recent clinical isolates of enterococci, staphylococci and streptococci from North American medical centres.
    Barry AL; Fuchs PC; Brown SD
    J Antimicrob Chemother; 1998 Nov; 42(5):651-5. PubMed ID: 9848451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quinupristin/dalfopristin: spectrum of activity, pharmacokinetics, and initial clinical experience.
    Low DE
    Microb Drug Resist; 1995; 1(3):223-34. PubMed ID: 9158779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Vancomycin-resistant enterococci: in vitro activity of quinupristin / dalfoprostin (RP 59500)].
    Betriu C; Valverde JF; Culebras E; Gómez M; Sánchez A; Palau ML; Picazo JJ
    Enferm Infecc Microbiol Clin; 1999; 17(7):335-9. PubMed ID: 10535185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group.
    Nichols RL; Graham DR; Barriere SL; Rodgers A; Wilson SE; Zervos M; Dunn DL; Kreter B
    J Antimicrob Chemother; 1999 Aug; 44(2):263-73. PubMed ID: 10473234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.